# OnCo record nct06362369 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06362369/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06362369", "NCT06362369" ;
  schema:name "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy"@en ;
  schema:description "A phase 1/2 trial of Ipilimumab, Nivolumab in metastatic cancer and melanoma, run by 7 Hills Pharma, LLC, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06362369/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06362369> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2024-08-23" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/mesothelioma/>, <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/nivolumab/> .